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Associations of wheezing phenotypes with late
asthma outcomes in the Avon Longitudinal Study
of Parents and Children: A population-based birth
cohortRaquel Granell, PhD, A. John Henderson, MD, and Jonathan A. Sterne, PhD Bristol, United KingdomBackground: Variable patterns of childhood wheezing might
indicate differences in the cause and prognosis of respiratory
illnesses. Better understanding of these patterns could facilitate
identificationofmodifiable factorsrelated todevelopmentofasthma.
Objectives: We characterized childhood wheezing phenotypes
from infancy to adolescence and their associations with asthma
outcomes.
Methods: Latent class analysis was used to derive phenotypes
based on patterns of wheezing recorded at up to 14 time points
frombirth to 16½ years among 12,303 participants from theAvon
Longitudinal Study of Parents and Children. Measures of lung
function (FEV1, forced vital capacity [FVC], and forced
expiratory flowbetween 25%and75%[FEF25-75]) and fraction of
exhaled nitric oxide (FENO) were made at 14 to 15 years of age.
Results: Six wheezing phenotypes were identified: never/
infrequent, preschool-onset remitting, midchildhood-onset
remitting, school age–onset persisting, late childhood–onset
persisting, and continuous wheeze. The 3 persistent phenotypes
were associated with bronchodilator reversibility of 12% or
greater (BDR) from baseline (odds ratio [OR] range, 2.14-3.34), a
FENO value of 35 ppb or greater (OR range, 3.82-6.24), and lung
function decrements (mean range of differences:20.22 to20.27
SD units (SDU) for FEV1/FVC ratio and20.21 to20.33 SDU for
FEF25-75) compared with never/infrequent wheeze.
Midchildhood-onset (4½ years) remitting wheeze was associated
withBDR (OR, 1.77; 95%CI, 1.11-2.82), a FENO value of 35 ppb or
greater (OR, 1.72; 95% CI, 1.14-2.59), FEV1/FVC ratio
decrements (OR,20.22 SDU; 95%CI,20.36 to20.08 SDU), and
FEF25-75 decrements (OR,20.16 SDU; 95% CI,20.30 to20.01
SDU). Preschool-onset (18 months) remitting wheeze was only
associated with FEV1/FVC ratio decrements (OR,20.15 SDU;
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106020.14 SDU; 95% CI,20.24 to20.04 SDU). The persisting
phenotypes showed evidence of sex stratification during
adolescence.
Conclusions: Early childhood–onset wheezing that persists into
adolescence represents the clearest target group for
interventions to maximize lung function outcomes. (J Allergy
Clin Immunol 2016;138:1060-70.)
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Asthma is a heterogeneous disease that displays phenotypic
variation throughout the life course. Prospective longitudinal
studies date the origins of a high proportion of asthma cases to
early childhood,1 and variations in the natural history of child-
hood wheezing are associated with different long-term out-
comes.2 Therefore the search for causal factors influencing the
development and natural course of asthma has focused on early
life. Cohort studies recruited in pregnancy or soon after birth
have examined associations between early-life influences and
childhood asthma, but only a few factors with modest effects
have been identified, and these do not explain recent increases
in childhood asthma prevalence. A possible explanation for
difficulties in identifying causes of childhood wheezing is that
phenotypic heterogeneity is a manifestation of underlying
differences in the pathophysiology of asthma endotypes, each
having different genetic and environmental influences. Character-
ization of wheezing phenotypes in children might help clarify the
underlying mechanisms through which asthma occurs and
improve the power to detect causal factors.
A seminal example of a temporal approach to characterizing
wheezing phenotypes reported in 1995 by the Tucson Children’s
Respiratory Study3 drew attention to the distinction between tran-
sient early wheezing and persistent or later-onset wheezing in
their associations with subsequent asthma history. Subsequently,
we applied data-driven approaches to identify 6 wheezing
phenotypes using repeated measures of wheezing in the Avon
Longitudinal Study of Parents and Children (ALSPAC).2 Our
methods and results have been replicated/validated in several
independent cohorts, with remarkable similarity in the patterns
of wheezing phenotypes characterized in different populations.4,5
Wheezing phenotypes defined by using this approach have clear
differences in their associations with clinical markers of asthma,2
andwe have also reported associations with early risk factors6 and
differences in genetic associations, suggesting that these are
distinct biological entities.7,8 Others have shown face validity of
statistically derived phenotypes compared with those defined by
using conventional clinical criteria and identified a novel clinical
phenotype characterized by unremitting wheeze, low lung
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diagnosis.9 However, to date, there have been few novel insights
into how modifiable environmental factors might influence the
onset of specific asthma subtypes, which would be a prerequisite
for primary or secondary prevention of disease.
Adolescence is a crucial period, as is very early childhood, in
the natural history of asthma and wheezing illnesses. The most
obvious manifestation is the well-described ‘‘sex switch’’ in
asthma prevalence that occurs during the transition from early
childhood tomidchildhood, whenmale asthma predominates, to a
female preponderance in young adults.10 There has been much
speculation that hormonal influences, particularly the effect of es-
trogens on inflammation, could underpin this change by
increasing asthma incidence in postpubertal female subjects.11
However, adolescence is a time of great changes in lifestyle and
behaviors, as well as biological and physiologic processes. There-
fore environmental risk factors during this period might influence
asthma natural history and thus be amenable to modification.
The aims of this study were to define extended wheezing
phenotypes byusing repeatmeasurements ofwheezemade regularly
during the first 16½ years of life and to investigate associations of
these extended phenotypes with physician-diagnosed asthma, lung
function, and FENO measures at age 14 to 15 years.METHODS
ALSPAC is a longitudinal, population-based birth cohort study that
included 14,062 live-born children. The study protocol has been described
previously,12 and further details can be found in the Methods section in this
article’s Online Repository at www.jacionline.org. Ethical approval for the
study was obtained from the ALSPAC Ethics and Law Committee and Local
Research Ethics Committees. The study Web site contains details of all
the data that are available through a fully searchable data dictionary at
www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/.Asthma, atopy, and lung function outcomes
Doctor-diagnosed asthma ever was defined based on parental report at
91 months (7½ years) and 166 months (14 years). Based on parental report of
doctor-diagnosed asthma ever at 91 months (7½ years) and 166 months
(14 years) and parental report of current asthma at 166 months (14 years), we
defined asthma status as follows: no asthma if the subject never had
doctor-diagnosed asthma, remittent if doctor-diagnosed asthma was reported
by 7½ years but no asthma symptoms were reported at 14 years, incident if
doctor-diagnosed asthma was reported by 14 years but not at 7½ years, and
persistent if doctor-diagnosed asthma was reported at 7½ and 14 years and
asthma symptoms were reported at 14 years.
Atopy was measured at a research clinic at age 7½ years, as previously
described.13
Spirometry was done in a research clinic at ages 8½ and 15 years by using
methods described previously.14 Lung function at 15 years was defined as the
highest of 3 measures before and 15 minutes after receiving 400 mg of salbu-
tamol administered by usingmetered aerosol and a spacer.15,16 Postsalbutamollung function was used as the primary outcome of this study. Presalbutamol
lung function measures were used for sensitivity analyses and for comparison
with findings at 8 years. FEV1, forced vital capacity (FVC), and forced
expiratory flow between 25% and 75% (FEF25-75) were converted into sex-,
age-, and height-adjusted SD units (SDU).17,18 From presalbutamol and
postsalbutamol lung functionmeasurements, we calculated percentage change
of FEV1 from baseline as follows:
([Post-FEV1] 2 [Pre-FEV1])/(Pre-FEV1 3 100%)
and defined a change of 12% or greater as evidence of bronchodilator
reversibility (BDR).
A fraction of exhaled nitric oxide (FENO) value of greater than 35 ppb was
used to define the likely presence of eosinophilic airway inflammation.19
Additional details of spirometric methods are provided in the Methods section
in this article’s Online Repository.Early wheezing phenotypes at 6 to 81 months of
age
Phenotypes of early childhood wheezing based on children’s history of
wheezing from 6 months to 81 months (7 years) of age were previously
identified and published2: (1) never/infrequent wheeze (68% of children) was
defined as an approximately 10% prevalence of wheezing at 6 months and
decreasing prevalence of sporadic wheeze thereafter, including children
who never reported wheeze; (2) transient early wheeze (10%) was defined
as a 50% to 60% prevalence of wheeze up to 18 months, decreasing to low
prevalence from 42 months; (3) prolonged early wheeze (8%) was defined
as a peak prevalence of wheeze of around 65% at 30 months, decreasing to
low prevalence from 69 months; (4) intermediate-onset wheeze (2%) was
defined as a low prevalence of wheeze up to 18 months, increasing rapidly
to high prevalence from age 42 months; (5) late-onset wheeze (5%) was
defined as an approximately 20% prevalence of wheeze up to 42 months,
increasing to more than 50% prevalence thereafter; and (6) persistent wheeze
(7%) was defined as a 65% prevalence of wheeze at 6 months and
approximately 90% prevalence thereafter.
Latent class analysis
Parental reports of children’s wheezing were obtained from questionnaires
sent to mothers at approximately annual intervals from 6 to 198 months
(16½ years) and used in a longitudinal latent class analysis to define
phenotypes of wheezing, as previously described.2,20 Starting with a model
assuming 3 phenotypes, we compared models with increasing numbers of
phenotypes using the Bayesian information criterion, the model entropy,
and the Lo-Mendell-Rubin adjusted likelihood ratio tests to compare models
with increasing numbers of phenotypes.21 The current article uses results
based on analysis of participants with at least 2 responses to questionnaires
about wheezing (n 5 12,303 participants, excluding triples and quadruples)
because these analyses yielded similar results to those based on complete
cases (n5 3170 participants, see Table E1 in this article’s Online Repository
at www.jacionline.org). Based on the optimal 6-class model (Fig 1), we ran 2
additional models:
1. A sex-stratified model allowing the trajectory of wheezing phenotypes to
differ between male and female subjects (Fig 2): We estimated the prevalence
of wheezing in the extended wheezing phenotypes separately for male and
female subjects and constructed single omnibus Wald tests (model test in
Mplus) to test equality for each pair of wheezing phenotypes in turn (sex
invariance of the optimal 6-class model). The null hypothesis of this test is
no difference in the trajectory of wheezing for male and female subjects.
We reported in Table I the mean difference of the probability of wheezing
(based on the 14 time points) and the Wald test P value for each wheezing
phenotype.
2. Model with atopy (skin prick testing at 7½ years) as a covariate (see
Fig E1 in this article’s Online Repository at www.jacionline.org): This model
allows the shape of the wheezing phenotypes to differ from the model without
atopy; we report prevalence of atopy by phenotype.
P values (x2 test) from the logistic regression models using female subjects
as the baseline group were reported in Table II to examine sex differences
FIG 1. Estimated prevalence of wheezing at each time point from birth to 16½ years for each of the
6 wheezing phenotypes identified by using latent class analysis in 12,303 participants with at least
2 observations of wheeze.
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wheezing phenotypes were examined by usingmultinomial logistic regression
models weighted for the probability of each subject belonging to each
phenotype (details are shown in the Methods section and Table E2 in this ar-
ticle’s Online Repository at www.jacionline.org). We identified the following
variables as being associated with at least 1 of the wheezing phenotypes and
adjusted for them in subsequent analyses: sex, maternal lower education level,
having at least 1 sibling (parity), maternal history of asthma or allergy,
maternal smoking during pregnancy, maternal anxiety during pregnancy,
low birth weight (<2.5 kg), preterm delivery (<37 weeks’ gestation), and
day care attendance during the first year.
All analyses were donewithMplus 7.1 software (2006; Muthen &Muthen,
Los Angeles, Calif) and Stata 13.1 software (StataCorp, College Station, Tex).RESULTS
Characteristics of the study population
Among 12,303 participants with at least 2 observations of
wheezing from birth to 16½ years of age (the study population),
3,170 had complete data from all 14 questionnaires. Character-
istics of participants with and without complete data are
compared in Table E1. Participants with complete data were
less likely to come from socially deprived backgrounds (lower
prevalence of lower maternal education and maternal smoking)
and had lower prevalence of reported wheezing in early childhood
than participants with missing data. Corresponding results based
on analysis of participants with complete reports of wheezing
(n 5 3,170) are available from the authors on request. Fig E2 in
this article’s Online Repository at www.jacionline.org shows
the distribution of the number of observations of wheeze.
Table II reports characteristics of the study population by sex.
A total of 6330 participants were male, and 5973 were female.
A similar proportion ofmale and female subjects had an asthmatic
or allergic mother (46.4% male subjects vs 46.0% femalesubjects), at least 1 sibling (55.4% vs 54.4%), low birth weight
(4.9% vs 5.1%), and attended day care during the first year
(6.1% vs 6.0%). Male subjects were more exposed to maternal
smoking during pregnancy (27.2% vs 25.0%, P 5 .009), and
more male subjects were born preterm (6.5% vs 5.1%,
P 5 .002) compared with female subjects. The prevalence of
wheezing was higher in male compared with female subjects
from 6 months (29.7% vs 22.3%, P < .001) to 166 months
(12.3% vs 9.7%, P < .001); however, the prevalence of wheezing
was similar at 198 months (10.4% vs 10.6%, P 5 .88). The
prevalence of atopy determined by using skin prick tests at
7½ years was higher in male than female subjects (24.5% vs
17.4%, P < .001).Late-childhood asthma outcomes
Table III shows the distributions of longitudinal and late-
childhood asthma outcomes in the study population and restricted
to participants with complete data on confounding variables.
Among the phenotypes of wheezing from 0 to 7 years defined
in our previous work,2 the most frequently occurring were tran-
sient early (1190 [10.2%] participants), prolonged early (822
[7.0%] participants), and persistent (899 [7.7%] participants)
wheezing. Based on reports of doctor-diagnosed asthma ever by
7½ and 14 years, 1637 (23.2%) participants had experienced
asthma by age 14 years, 707 (11.9%) had asthma by 7½ years
but no asthma at 14 years (remittent asthma), 378 (6.3%) had
incident asthma between 7½ and 14 years, and 446 (7.5%) had
persistent asthma by 14 years. A total of 319 (8.3%) participants
had BDR, and 680 (31.5%) participants had FENO values of
greater than 35% ppb at 15 years. These proportions were similar
when data was restricted to participants with complete data on
confounders.
FIG 2. Estimated prevalence of wheezing at each time point from birth to 16½ years for each of the
6 wheezing phenotypes identified by using latent class analysis in 12,303 participants with at least
2 observations of wheeze by sex.
TABLE I. Distribution of the extended phenotypes of wheezing from 0 to 16½ years among female (n 5 5973) and male (n 5 6330)
members of the study population
Phenotype Female subjects, no. (%)* Male subjects, no. (%)* Mean probability differencey P value, Wald test
Never/infrequent wheeze 3800 (63.6) 3499 (55.3) 0.01 .004
Preschool-onset remitting wheeze 1020 (17.1) 1333 (21.1) 0.03 .33
Midchildhood-onset remitting wheeze 444 (7.4) 442 (7) 0.06 .53
School-age–onset persisting wheeze 190 (3.2) 312 (4.9) 0.13 .0061
Late childhood–onset persisting wheeze 260 (4.4) 357 (5.6) 0.10 <.0001
Continuous wheeze 259 (4.3) 387 (6.1) 0.04 .26
*Most probable phenotype based on model estimated probabilities, including sex as a known class.
For each phenotype, the difference between male and female subjects of the probability of wheezing at each time point were calculated and then averaged.
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phenotypes at 0 to 16½ years of age
The best-fitting model based on 12,303 participants with
reports of wheezing from 0 to 16½ years of age resulted in 6
extended wheezing phenotypes. Trajectories of prevalence of
wheeze for each of these phenotypes are presented in Fig 1. We
labeled the wheezing phenotypes as follows:
1. never/infrequent wheeze (estimated number of participants,
7372 [59.9%]) with approximately 10% prevalence of
wheezing at 6 months and decreasing prevalence ofsporadic wheeze thereafter, including participants who
never reported wheeze;
2. preschool-onset remitting wheeze (2298 [18.7%]) with
50% to 60% prevalence of wheeze up to 18 months,
decreasing to less than 10% prevalence from 69 months;
3. midchildhood-onset remitting wheeze (923 [7.5%]) with
peak prevalence of wheeze around 84% at 54 months,
decreasing to less than 20% from 128 months;
4. school age–onset persisting wheeze (524 [4.3%]) with less
than 20% prevalence of wheeze up to 42 months,
TABLE II. Characteristics of participants with at least 2 observations of wheeze (study population, n 5 12,303) by sex
Participants with 2-14 observations of wheezing (n 5 12,303)
Male subjects (n1 5 6,330) Female subjects (n2 5 5,973)
P value (x2 test)No./total Percent No./total Percent
Potential confounders
Lower maternal education* 3,715/5,848 63.5 3,446/5,487 62.8 .43
Having >_1 sibling (parity) 3,202/5,777 55.4 2,946/5,413 54.4 .29
Maternal history of asthma or allergy 2,652/5,721 46.4 2,487/5,411 46.0 .68
Maternal smoking during pregnancy 1,570/5,774 27.2 1,364/5,449 25.0 .009
Maternal anxiety during pregnancy 1,193/5,434 22.0 1,117/5,106 21.9 .92
Low birth weight (<2.5 kg) 293/5,951 4.9 282/5,580 5.1 .75
Preterm delivery (<37 wk) 391/6,023 6.5 291/5,651 5.1 .002
Maternal smoking during first year 1,334/5,557 24.0 1,195/5,255 22.7 .12
Day care attendance during first year 333/5,493 6.1 308/5,136 6.0 .89
Variables used in latent class model
Reported wheezing at:
6 mo 1,683/5,673 29.7 1,191/5,331 22.3 <.001
18 mo 1,730/5,622 30.8 1,255/5,239 24.0 <.001
30 mo 1,312/5,144 25.5 932/4,801 19.4 <.001
42 mo (3½ y) 1,000/5,159 19.4 756/4,814 15.7 <.001
54 mo 1,035/4,861 21.3 739/4,530 16.3 <.001
69 mo 767/4,434 17.3 561/4,162 13.5 <.001
81 mo 646/4,321 15.0 481/4,074 11.8 <.001
91 mo 526/4,218 12.5 352/3,984 8.8 <.001
103 mo (8½ y) 626/4,160 15.0 424/4,000 10.6 <.001
128 mo 567/3,848 14.7 368/3,797 9.7 <.001
140 mo 508/3,692 13.8 361/3,707 9.7 <.001
157 mo 431/3,490 12.3 309/3,508 8.8 <.001
166 mo 427/3,475 12.3 336/3,455 9.7 <.001
198 mo (16½ y) 286/2,739 10.4 306/2,896 10.6 .88
Atopy at 7½ y (skin prick test) 825/3,364 24.5 578/3,327 17.4 <.001
*Educated to the General Certificate of Education level (school-leaving certificate) or lower.
Anxious mothers were defined as being in the fourth quantile of the Crown-Crisp Experiential Index.
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103 months and then decreasing to 46% at 198 months;
5. late childhood–onset persisting wheeze (580 [4.7%]) with
32% prevalence at 6 months, decreasing up to 91 months
and increasing rapidly to a peak prevalence of 71% at
166 months; and
6. continuous wheeze (606 [4.9%]) with approximately 41%
prevalence of wheeze at 6 months and prevalence between
62% and 97% thereafter.
Sex-specific wheezing phenotypes
Fig 2 shows trajectories of prevalence of wheeze estimated
separately in male and female subjects for each phenotype. The
sex-stratified wheezing phenotypes were similar to the extended
phenotypes and were given the same labels (see above). The prev-
alence of the preschool-onset remitting phenotype was lower for
female (17%) than male (21%) subjects (Table I). There were
modest differences in prevalence of the school age–onset
persisting phenotype (3% of female and 5% of male subjects).
The prevalence of both the late childhood–onset persisting and
continuous wheeze phenotypes was approximately 4% for female
and 6% for male subjects. The never/infrequent wheeze
phenotype had a prevalence of 64% in female subjects and 55%
in male subjects.
The results from the Wald test strongly supported sex
stratification of the school age–onset persisting (mean probability
difference, 0.13; P 5 .0061) and late childhood–onset persisting(mean probability difference, 0.10; P < .0001) phenotypes
(Table I), but no differences were observed for the other
phenotypes, excluding never/infrequent wheeze. There was clear
evidence (P 5 .004) that the never/infrequent wheeze phenotype
differed between male and female subjects, but this difference
was explained by between-sex differences in the prevalence of
wheeze at the first (0.04) and last (0.03) time points within this
phenotype. For other time points the between-sex differences
were, on average, 0.01 or less, and the test P value increased to
.38 in a sensitivity analysis excluding the first and last time points.
Model including atopy
Fig E1 depicts the slightly modified wheezing phenotype
model when including atopy as an additional covariate. The
phenotypes with the highest prevalence of atopy were the school
age–onset persisting (72% atopic) and continuous wheezing
(69% atopic) phenotypes, followed by the late childhood–onset
persisting (48% atopic) and midchildhood-onset remitting (23%
atopic) phenotypes. The never/infrequent wheeze (14% atopic)
and preschool-onset remitting (11% atopic) phenotypes had the
lowest prevalence of atopic participants.Validation of the extended wheezing phenotypes
To validate the extended wheezing phenotypes, we examined
the proportion of participants classified as having no asthma,
remittent asthma, incident asthma, and persistent asthma in each
wheezing phenotype (Fig 3, A). As expected, the never/infrequent
TABLE III. Longitudinal and late-childhood outcomes in the study population and restricted to participants with complete data on
confounders
All participants in study
population (n 5 12,303)
Restricted to participants with complete data
on confounders (n 5 8,925)§
Total no.* No. (%) or IQR Total no.* No. (%) or IQR
Longitudinal outcomes
Wheezing phenotypes at 0-7 y 11,674 8,925
Never/infrequent wheezing 7,961 (68.2) 6,154 (69.0)
Transient early wheezing 1,190 (10.2) 884 (9.9)
Prolonged early wheezing 822 (7.0) 623 (7.0)
Intermediate-onset wheezing 275 (2.4) 223 (2.5)
Late-onset wheezing 527 (4.5) 410 (4.6)
Persistent wheezing 899 (7.7) 631 (7.1)
Asthma status at 0-14 y 5,960 5,053
No asthma 4,429 (74.3) 3,774 (74.7)
Asthma by 7½ y but no asthma at 14 y 707 (11.9) 581 (11.5)
Incident asthma between 7½ and 14 y 378 (6.3) 317 (6.3)
Persistent asthma by 14 y 446 (7.5) 381 (7.5)
Late-childhood outcomes
Ever doctor-diagnosed asthma by 14 y 7,052 1,637 (23.2) 5,595 1,270 (22.7)
BDR at 15 y 3,831 319 (8.3) 3,063 258 (8.4)
FENO >_35% at 14-15 y 2,159 680 (31.5) 1,721 537 (31.2)
z Score FEV1 (SDU) at 15 y 3,657 20.61 to 0.64 3,046 20.62 to 0.64
z Score FVC (SDU) at 15 y 3,812 20.63 to 0.65 3,177 20.63 to 0.64
z Score FEV1/FVC ratio at 15 y 3,657 20.52 to 0.72 3,046 20.51 to 0.72
z Score FEF25-75 (SDU) at 15 y 3,812 20.66 to 0.63 3,177 20.67 to 0.64
IQR, Interquartile range.
*Number of participants with data available.
Height-, age-, and sex-adjusted standard SDUs.
BDR of FEV1 defined as a change of greater than 12% in FEV1.
§Confounders: sex, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, and preterm delivery.
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pants with no asthma, whereas the continuous wheeze phenotype
had the highest proportion (82%) of participants with persistent
asthma. The preschool-onset remitting phenotype mostly
overlapped with no asthma (73%) and remittent asthma (20%),
whereas the midchildhood-onset remitting phenotype mostly
overlapped with remittent asthma (58%), no asthma (21%), and
persistent asthma (16%). The school age–onset persisting
phenotype mostly overlapped with persistent asthma (47%),
remittent asthma (28%), and no asthma (14%). The late
childhood2onset persisting phenotype mostly overlapped with
incident asthma (50%), no asthma (35%), and persistent
asthma (11%).
Fig 3, B, shows the proportion of participants classified with
each of the previously published early childhood wheezing
phenotypes for each extended wheezing phenotype. The never/
infrequent wheeze phenotype had the highest proportion of early
childhood never/infrequent wheezing (98% overlap), and the
continuous wheeze phenotype overlapped mainly with early
childhood persistent wheeze (66%) and intermediate-onset
wheeze (25%). The preschool-onset remitting phenotype overlap-
ped with early childhood transient early wheezing (53%) and
prolonged early wheezing (33%). The midchildhood-onset remit-
ting phenotype overlapped with early childhood persistent
wheezing (60%) and with prolonged early, intermediate-onset,
and late-onset wheezing (prevalence, 11% to 15%). The school
age2onset persisting phenotype overlapped with early childhood
late-onset wheezing (57%) and never/infrequent wheezing
(24%). The late-childhood persisting phenotype mainly overlap-
ped with early childhood never/infrequent wheezing (74%).Associations of extended wheezing phenotypes
with doctor-diagnosed asthma, FENO, and BDR at 14
to 15 years of age
All wheezing phenotypes were associated with substantially
higher odds of doctor-diagnosed asthma ever at 14 years
compared with the never/infrequent wheeze phenotype
(Table IV). Associations were particularly strong for continuous
(adjusted odds ratio [OR], 368; 95% CI, 181-747), school
age2onset persisting (OR, 50.0; 95% CI, 35.2-71.0), and
midchildhood-onset remitting (OR, 25.1; 95% CI, 19.4-32.4)
wheeze. The school age2onset persisting, late childhood2onset
persisting, and continuous wheeze phenotypes were strongly
associated with FENO values of 35 ppb or greater and BDR
compared with never/infrequent wheeze. The strongest associa-
tions were for continuous wheeze with FENO values of 35 ppb
or greater (adjusted OR, 6.74; 95% CI, 3.93-11.54) and school
age2onset persisting wheeze with BDR (OR, 3.34; 95% CI,
2.08-5.35). Midchildhood-onset remitting wheeze was associated
with FENO values of 35 ppb or greater (OR, 1.87; 95% CI,
1.23-2.84) and BDR (OR, 1.77; 95% CI, 1.11-2.82) compared
with never/infrequent wheeze. There was little evidence for
associations of preschool-onset remitting wheeze with either
FENO values of 35 ppb or greater or BDR.Associations of extended wheezing phenotypes
with lung function measures at 15 years
ContinuouswheezewasassociatedwithdecrementsofFEV1/FVC
ratio (mean difference,20.27 SDU; 95%CI,20.45 to20.09 SDU)
FIG 3. Validation of wheezing phenotypes at 0 to 16½ years with asthma status at 0 to 14 years (A) and
wheezing phenotypes at 0 to 7 years (B) in 12,303 participants with at least 2 observations of wheeze.
CW, Continuous wheeze; LCP, late childhood–onset persisting wheeze;MCR, midchildhood-onset remitting
wheeze; NI, never/infrequent wheeze; PSR, preschool-onset remitting wheeze; SAP, school age–onset
persisting wheeze.
TABLE IV. Adjusted associations of wheezing phenotypes at 0 to 16½ years with doctor-diagnosed asthma ever (n 5 5595), FENO
values (n 5 1721), and FEV1 reversibility (n 5 3063) at 14 to 15 years in participants with at least 2 observations of wheeze
Wheezing phenotype at 0-16½ y
Doctor-diagnosed asthma ever at 14 y FENO >_35 ppb at 14-15 y BDR >12% at 15 y
No. of asthmatic
patients/total*
Adjusted
OR (95% CI)y n1/total*
Adjusted
OR (95% CI)y n2/total*
Adjusted
OR (95% CI)y
Never/infrequent wheeze 272/3661 1 (reference) 290/1157 1 (reference) 139/2003 1 (reference)
Preschool-onset remitting wheeze 173/870 2.73 (2.22-3.36) 61/243 1.00 (0.73-1.35) 33/472 1.18 (0.81-1.70)
Midchildhood-onset remitting wheeze 231/337 25.1 (19.4-32.4) 42/102 1.87 (1.23-2.84) 21/204 1.77 (1.11-2.82)
School age–onset persisting wheeze 187/223 50.0 (35.2-71.0) 57/82 6.24 (3.82-10.21) 27/127 3.34 (2.08-5.35)
Late childhood–onset persisting wheeze 161/250 19.8 (15.0-26.2) 38/66 3.70 (2.30-5.95) 19/131 2.14 (1.28-3.58)
Continuous wheeze 246/254 367.6 (181-747) 49/71 6.74 (3.93-11.54) 19/126 2.61 (1.53-4.45)
n1, Number of participants with FENO vales of 20 ppb or greater; n2, number of participants with BDR.
*Number of participants with data available (approximated from modal assignment).
Adjusted for sex, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight, and day care attendance during
the first year.
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20.15 SDU) compared with never/infrequent wheeze (Table V).
The preschool- and midchildhood-onset remitting phenotypes were
associated with a small decrement of FEV1/FVC ratio (mean differ-
ence,20.15 SDU; [95%CI,20.25 to20.05 SDU] and20.22 SDU
[95% CI, 20.36 to 20.08 SDU]) and FEF25-75 (mean difference,
20.14 SDU [95% CI, 20.24 to 20.04 SDU] and 20.16 SDU
[95% CI, 20.30 to 20.01 SDU], respectively) compared with
never/infrequent wheeze. Midchildhood-onset remitting was also
associated with an increment of FVC (0.20 SDU; 95% CI,
0.06-0.34 SDU) compared with never/infrequent wheeze. School-
age–onset persisting wheeze was associated with small decrements
of FEV1/FVC ratio (20.22 SDU; 95% CI, 20.39 to 20.04 SDU),
and late childhood–onset persisting wheeze was associated with
small decrements of FEF25-75 (20.21 SDU; 95% CI, 20.38 to
20.04 SDU) compared with never/infrequent wheeze.
Crude associations are presented in Tables E3 and E4 in this ar-
ticle’s Online Repository at www.jacionline.org: the estimates
were little attenuated by adjustment for potential confounders.
Corresponding association with lung function measures at 8½
years are presented in Table E5 in this article’s Online Repository
at www.jacionline.org. The association of midchildhood-onset
remitting wheeze with FVC at 15 years was not observed at
8 years. However, associations of preschool-onset remitting,
midchildhood-onset remitting, school age–onset persisting, and
continuous wheezewith FEV1/FVC ratiowere observed at 8 years
and appeared attenuated at 15 years, whereas associations ofpreschool-onset remitting, midchildhood–onset remitting,
late childhood–onset persisting, and continuous wheeze with
FEF25-75 were observed at 8 years and increased at 15 years.
Table E6 in this article’s Online Repository at www.jacionline.
org reports the associations with presalbutamol lung function
measures at 15 years, and Table E7 in this article’s Online
Repository at www.jacionline.org reports the associations with
presalbutamol lung function measures at 15 years further adjusted
for lung function measures at 8½ years.DISCUSSION
Main findings
Based on analyses of wheezing measured on 14 occasions
between the ages 6 and 198 months in 12,303 participants in the
ALSPAC birth cohort study, we identified 6 phenotypes of
childhood wheezing and quantified their associations with
doctor-diagnosed asthma and objective measures of FENO,
BDR, and lung function in late childhood. Almost 60% of
participants were classified as having never or infrequently
wheezed, with wheezing in these participants being sporadic
and usually early. Two of the wheezing phenotypes identified
were characterized by remission of symptoms in later childhood,
and 3 were associated with persistent symptoms from onset in
midchildhood to late childhood or continuous symptoms from in-
fancy. Compared with the never/infrequent wheezing phenotype,
those phenotypes with remitting symptoms (preschool-onset
TABLE V. Adjusted association of wheezing phenotypes at 0 to 16½ years with lung function measures at 15 years
(postsalbutamol z scores) in participants with at least 2 observations of wheeze and spirometry done at 15 years
Wheezing phenotype
at 0-16½ y
FEV1 (SDU) at 15 y FVC (SDU) at 15 y
FEV1/FVC ratio
(SDU) at 15 y FEF25-75 (SDU) at 15 y
No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y
Never/infrequent wheeze 1997 0 (reference) 2094 0 (reference) 1997 0 (reference) 2094 0 (reference)
Preschool-onset remitting
wheeze
463 20.03 (20.12 to 0.07) 477 0.05 (20.05 to 0.14) 463 20.15 (20.25 to 20.05) 477 20.14 (20.24 to 20.04)
Midchildhood-onset remitting
wheeze
203 0.09 (20.06 to 0.23) 209 0.20 (0.06 to 0.34) 203 20.22 (20.36 to 20.08) 209 20.16 (20.30 to 20.01)
School-age–onset persisting
wheeze
127 0.08 (20.10 to 0.26) 131 0.18 (0.00 to 0.35) 127 20.22 (20.39 to 20.04) 131 20.16 (20.33 to 0.02)
Late childhood–onset
persisting wheeze
130 20.02 (20.19 to 0.15) 135 0.02 (20.15 to 0.18) 130 20.08 (20.25 to 0.09) 135 20.21 (20.38 to 20.04)
Continuous wheeze 126 20.08 (20.27 to 0.10) 131 0.04 (20.14 to 0.22) 126 20.27 (20.45 to 20.09) 131 20.33 (20.51 to 20.15)
*Number of participants with data available (approximated from modal assignment).
Adjusted for sex, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight, and day care attendance during
the first year.
TABLE VI. Strength and direction of associations between extended wheezing phenotypes and clinical outcomes at 14 to 15 years
Phenotype Asthma FENO >_35 ppb BDR FEV1 FVC FEV1/FVC ratio FEF25-75
Preschool-onset remitting wheeze O 3 3 3 3 Y Y
Midchildhood-onset remitting wheeze OO O O 3 [[ YY Y
School-age–onset persisting wheeze OOO OOO O 3 3 YY 3
Late childhood–onset persisting wheeze OO OO O 3 3 3 YY
Continuous wheeze OOOO OOO O 3 3 YY YY
The strength of association of each wheezing phenotype with each outcome is represented by the number of symbols (O, Y, and [), with3 representing absence of association with
that outcome.
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comprising 27% of the study population, were associated with
lung function deficits in adolescence, with the later-onset group
also having evidence of eosinophilic inflammation and BDR at
age 15 years. All 3 phenotypes with symptoms persisting to
adolescence were characterized by strong associations with diag-
nosed asthma, BDR, and high FENO measurements, with contin-
uous wheeze being the most strongly associated with these
outcomes. These associations are summarized in Table VI.Results in the context of the existing literature
Our approach to classifying childhood wheezing up to age
7 years by its temporal patterns using latent class analysis2 has
been replicated15 and validated4,5 by independent studies and
has utility in identifying clinically relevant phenotypes with
high sensitivity and specificity.9 However, there is uncertainty
about whether phenotypes classified this way represent distinct
pathophysiologic processes leading to different long-term out-
comes or whether outcome variation is related to the duration
and severity of a single disease process.
Several cohort studies of asthma beginning in childhood have
followed lung function development through to adult life. In the
Melbourne Asthma Study22 there was a relationship between the
severity of wheezing illness in early childhood and the probability
of persistent asthma in adulthood and obstructive airway function
to age 50 years. In keeping with longitudinal lung function mea-
surements from midchildhood (age 9 years) in the Dunedin
cohort1 and from infancy in the Tucson Children’s RespiratoryStudy,23 it appeared that lung function deficits were already estab-
lished by school age and adult obstructive airway functionwas ex-
plained by tracking of these deficits into adult life rather than by a
more rapid decrease of adult lung function. Studies with lung
function measurements from early infancy have reported
associations of lung function deficits shortly after birth with the
development of asthma in childhood,24,25 but there is inconsis-
tency regarding the trajectories of lung function development
from birth to school age between these and the Tucson study,
which suggested that children who had wheezing and asthma
had near-normal lung function at birth but airway obstruction
by 6 years, which then tracked to adulthood. In the Danish
COPSAC study low lung function was present soon after birth,
with further deviation from lung function development in healthy
infants occurring during the first 7 years. The authors estimated
that 40% of the lung function deficit at 7 years in children with
asthma was explained by low lung function at birth and the
remaining 60% by early-life developmental processes. They
also reported that lung function–associated genetic polymor-
phisms in adults were associated with lung function development
form birth to 7 years but not with neonatal lung function,26
suggesting that the mechanisms influencing these 2 aspects are
different.
Our data are consistent with the notion that early onset of
wheezing symptoms is associated with establishment of low lung
function by school age, which persists to adolescence, whereas
late-onset wheezing (after 7 years) was not associated with
postbronchodilator airway obstruction by age 15 years. All
phenotypes with evidence of wheezing during the first 7 years
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adolescence in contrast to the late childhood–onset persisting
phenotype. Although the greatest deficit was present in the group
with early wheeze onset (6 months after birth) that persisted until
adolescence, this supports onset of wheezing illness in early
childhood having a greater influence than its duration after onset
and hence a window of development when intervention might be
possible.
Our findings are compatible with a multifactorial etiology of
low lung function in adolescence associated with wheezing
phenotypes and asthma in childhood. It is likely that airway
developmental abnormalities around the time of birth contribute
both to the likelihood of asthma and its consequences. In the
Tucson study those with the lowest airway function soon after
birth had transient wheezing, and their lung function appeared to
regress to the mean during the first 6 years,27 although the lowest
quartile of lung function at birth was associated with low lung
function at age 22 years in the same cohort.23 Transient wheeze
in the Melbourne study and remitting wheeze in the Dunedin
study were both associated with smaller deficits of lung function
in adulthood than those with persistent asthma phenotypes.
What causes lung function to decrease during the preschool
years in childrenwith wheezing illnesses is a matter of speculation.
Airway inflammation has been reported to be associated with signs
of remodeling, even in early childhood,28 and it is conceivable that
untreated airway inflammation in early life could result in
progressive irreversible obstruction, although the processes in in-
fancy probably differ from those associated with asthma in older
children.29 It is notable that intervention with inhaled corticoste-
roids to treat mild-to-moderate asthma in the Childhood Asthma
Management Program study after age 5 years30 and children at
high risk for asthma aged 2 to 3 years in the Prevention of Early
Asthma in Kids (PEAK) study31 did not provide evidence that
anti-inflammatory treatment was effective in improving lung
function in later childhood in either of these populations.
Some of the lung function deficits that we observed could be
accounted for by current asthma at the time of measurement, with
evidence of associated asthma, BDR, and eosinophilic airway
inflammation present in all wheeze phenotypes, except preschool-
onset remitting wheeze. However, there was still evidence of
airway obstruction after bronchodilation in some of these sub-
jects, particularly those with persisting wheeze, suggesting that at
least a component of airway obstruction in these participants was
irreversible. We cannot infer from these data the nature of the
complex relationship between airway development, asthma,
airway inflammatory responses, and remodeling in the causal
pathway of low adult lung function. It appears that wheeze that
starts early in life (in the preschool years) and persists to
adolescence is most strongly associated with airway obstruction
in adolescence, and a focus on identifying factors in this
population that lead to persistence of symptoms might help to
identify targets for intervention other than with corticosteroids.
We found a higher prevalence of atopy in the wheezing
phenotypes that were more strongly associated with persistence
of wheezing after onset (including continuous wheeze from
infancy) than with remitting phenotypes. An association of atopy
with persistent asthma symptoms has been reported
previously32,33 and might be explained by the association of
eosinophilic airway inflammation with asthma severity and
persistence in childhood.34,35 Eosinophilic airway inflammation
has been identified in preschool children with confirmedwheezing,28 and high FENO levels are associated with persistent
compared with transient wheeze in this age group.36
Attention has recently focused on better characterization of the
temporal pattern of allergic sensitization in children, and it is
possible that different pathways of sensitization are associated
with different pathophysiology of wheezing illnesses in early
childhood. Belgrave and others have reported associations of a
multiple early allergy phenotype37 with increased airways resis-
tance through childhood to age 11 years.38 Joint latent class
models of atopy and wheezing have also shown differences in as-
sociations of early-life exposures between wheezing phenotypes
associated with high and low levels of atopy.39 We were limited
in our ability to replicate these findings in our cohort because
we had only 1 measurement of sensitization at age 7 years.
We found strong evidence of between-sex differences for the
school age–onset and late childhood–onset persisting phenotypes.
For the school age–onset persisting phenotype, with wheeze
starting after 3½ years, the probability of wheezing between 9 and
16 years decreased substantially more in male subjects (0.72 to
0.22) than in female subjects (0.74 to 0.52). Thus this phenotype,
with wheeze starting after 3½ years, might be considered to have a
high probability of remission in male subjects during adoles-
cence. Consistent with other studies, we observed an early male
predominance of wheezing, but this had equalized by age
16 years. A sex switch toward female predominance of asthma
in early adulthood has been reported in other studies,1,40 and it has
been suggested that hormonal influences might play a role in
incident female asthma during and after puberty.41,42 Most of
the female participants in our study had reported menarche by
the age of 16 years, but we did not see strong evidence for a large
increase in asthma prevalence in female subjects by this age,
perhaps suggesting that if hormonal effects are causal in
promoting asthma in female subjects, they are unlikely to be
expressed in the short term but might exert their influences
through indirect mechanisms with a longer time lag.Strengths and limitations
An advantage of our study is the availability of data from a
large, unselected, population-based cohort followed to late
adolescence. For comparison, the Tucson Study reported on 826
children during the first 6 years,3 and the Dunedin study reported
on 613 subjects with complete respiratory data at 9 to 26 years.1
The Perth study of infant lung function reported outcomes at
11 years in 183 infants,43 and a cohort of 2860 infants in Perth
reported on asthma to age 6 years.44
Wheeze reported on up to 14 occasions (from 6 months to
nearly 16 years) was used in a data-driven (latent-class) approach
to derive childhood wheezing phenotypes, so that preconceptions
about phenotype structure did not affect the derived phenotype
groups. We were able to look at associations between the derived
childhood wheezing phenotypes and different measures of lung
function at 15 years, despite the fact that some phenotypes
represented relatively small proportions of children.
There are some limitations to our study design and findings.
The reports of wheezing used in the latent class analyses to derive
wheezing phenotypes were not always contemporaneous with
measurements of clinical outcomes: in particular, the latest
measurements of doctor-diagnosed asthma and lung function
were at ages 14 and 15 years, respectively. We think it is likely
that associations of these outcomes with wheezing phenotypes
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 4
GRANELL, HENDERSON, AND STERNE 1069will be similar to those had the outcomes been measured at the
time of the last wheezing measurement at age 16½ years because
wheezing phenotypes were derived from all available data from
6 months onward and therefore unlikely to be markedly
influenced by wheezing at a single time point.
A major limitation of latent class models is their application to
the clinical setting because children with wheezing cannot be
assigned prospectively to a particular phenotype, which has been
defined by post hoc data analysis. However, by demonstrating the
existence of different trajectories of wheezing illnesses through
childhood and their associated outcomes, we aim to identify those
phenotypes associated with adverse long-term outcomes that
might be amenable to intervention in early life. The challenge
is then to find associated biomarkers of these disease types that
can be applied to distinguish early wheeze that persists from
that which remits, investigate the pathophysiologic pathways
that exist at an early stage in these evolving phenotypes, and
use this information to derive interventions that might be
phenotype specific. Finally, we have been unable to verify the
findings of our study in an independent cohort, and replication
will be an essential first step to realizing the utility of hypothesis
generation based on our phenotypes.Conclusion
This study adds to our previous description of wheezing
phenotypes in children by extending knowledge of variation in
the natural history of wheeze from infancy through the critical
adolescent transition period to adulthood, during which the sex
distribution of asthma changes and lung development nears its
peak. We confirmed the importance of early childhood wheezing
illness in lung function development and identified the temporal
wheezing patterns most strongly associated with airway obstruc-
tion as wheeze starting before the age of 4 years and persisting
throughout childhood. The challenge is to translate this knowl-
edge by identifying clinically useful biomarkers associated with
disease phenotypes that can be measured in early childhood and
hence to enable the study of disease pathways associated with
unfavorable prognosis and development of targeted interventions
to modify the natural history of wheezing illnesses in young
children, a population in whom treatment with corticosteroids
appears to be ineffective in disease modification.
We are extremely grateful to all the families who took part in this study, the
midwives for their help in recruiting them, and the whole ALSPAC team,
which includes interviewers, computer and laboratory technicians, clerical
workers, research scientists, volunteers, managers, receptionists, and nurses.REFERENCES
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Participants
ALSPAC recruited 14,541 pregnant women resident in Avon, United
Kingdom,with expected dates of delivery fromApril 1, 1991, to December 31,
1992. This number (14,541) is the initial number of pregnancies for which the
mother enrolled in the ALSPAC study and had either returned at least 1
questionnaire or attended a ‘‘Children in Focus’’ clinic by July 19, 1999. Of
these initial pregnancies, there were 14,676 fetuses, resulting in 14,062 live
births and 13,988 children who were alive at 1 year of age. When the oldest
childrenwere approximately 7 years of age, an attemptwasmade to bolster the
initial sample with eligible cases who did not join the study originally. As a
result, when considering variables collected from the age of 7 years onward
(and potentially abstracted from obstetric notes), there are data available for
more than the 14,541 pregnancies mentioned above. The number of new
pregnancies not in the initial sample (known as phase I enrollment) that are
currently represented on the built files and reflecting enrollment status at the
age of 18 years is 706 (452 and 254 recruited during phases II and III,
respectively), resulting in an additional 713 children being enrolled. The
phases of enrollment are described in more detail in the cohort profile paper.E1
Therefore the total sample size for analyses using any data collected after the
age of 7 years is 15,247 pregnancies, resulting in 15,458 fetuses. Of this total
sample of 15,458 fetuses, 14,775 were live births, and 14,701 were alive at
1 year of age.
A 10% sample of the ALSPAC cohort, known as the Children in Focus
group, attended clinics at the University of Bristol at various time intervals
between 4 to 61 months of age. The Children in Focus group was chosen at
random from the last 6 months of ALSPAC births (1432 families attended >_1
clinic). Excluded were those mothers who had moved out of the area or were
lost to follow-up and those partaking in another study of infant development in
Avon.
Please note that the study Web site contains details of all data that are
available through a fully searchable data dictionary and reference the
following Web page:
http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/.
Skin prick tests
Atopy was measured at a research clinic at age 7½ years, as previously
described.E2 A positive response was defined as a mean wheal diameter of
greater than 2 mm with an absent response to negative control solution, and
atopy was defined as a positive response to 1 or more of house dust mite,
cat, or grass pollen.
FENO at 14 to 15 years
FENO values were measured online at a constant flow of 50 mL/s according
to European Respiratory Society and American Thoracic Society guidelines
by using a Sievers NOA-280i nitric oxide analyzer (GE Analytical Instru-
ments, Boulder, Colo).
Additionally, 758 children with less stringent criteria (individual exhala-
tions >5% deviation but at least 1 within the acceptable range of 10-200 ppb)
were included. FENO measurements were done before spirometric measure-
ments. Children were requested to omit their inhaled corticosteroids, if appli-
cable, 48 hours before their visit to the clinic. At the time of measurements, 14
(0.3%) children received oral steroids, 221 (5.2%) had a chest infection and/or
fever with a cold in the preceding 3 weeks, and 39 (0.9%) and 89 (2.1%) had
used short- or long-acting bronchodilators for 6 or 24 hours, respectively,
before the respiratory assessments. These children and those with less
stringent criteria of FENO values were included in our analyses because we
observed no differences in results when they were included or excluded.
Asthma status at 0-14 years
Using ever-reported doctor-diagnosed asthma at 91 and 166 months and
maternal report of asthma at 166 months, we derived the following asthma
status variable: no asthma if negative at both 91 and 166 months, remittent
asthma if positive at 91 months but negative at 166 months or positive at
both 91 and 166 months but negative maternal report of asthma in the last12months at 166months, incident asthma if negative at 91months but positive
at 166months, and persistent asthma if positive at both 91 and 166months and
positive maternal report of asthma in the last 12 months at 166 months.
Potential confounders
Weobtained details ofmaternal educational attainment (lower level defined
as educated to school leaving certificate at <_16 years of age), smoking history,
and personal history of asthma or allergy from questionnaires sent to the
mother during pregnancy. The child’s sex was obtained from delivery health
care records. Postnatal maternal questionnaires from 3 to 15months after birth
were used to ascertain environmental tobacco smoke exposure.
Statistical analysis
Associations of wheezing phenotypes with late asthma outcomes
(physician-diagnosed asthma and objective measurements of lung function
and FENO values) were examined by using logistic or linear regression
models weighted for the probability of each subject of belonging to each
phenotype to minimize the risk of bias caused by misclassification. These
probabilities were estimated previously and referred to as the posterior
probabilities.E3 Crude and adjusted ORs (for binary outcomes) and mean
differences (for continuous outcomes) were derived in relation to the never/
infrequent wheezing phenotype (reference group). Adjustment was done for
potential confounders: sex, maternal lower education level, having 1 or
more siblings (parity), maternal history of asthma or allergy, maternal
smoking during pregnancy, maternal anxiety during pregnancy (as being in
the fourth quantile of the Crown-Crisp Experiential Index),E4 low birth weight
(<2.5 kg), preterm delivery (<37 weeks), and day care attendance during the
first year.
RESULTS
A total of 6,330 (51.5%) participants were male, 5,139 (46.2%)
had an asthmatic or allergic mother, 2,934 (26.1%) were exposed
to maternal smoking during pregnancy, and 6,148 (54.9%) had at
least 1 sibling. Five hundred seventy-five (5.0%) had low birth
weight, and 682 (5.8%) were born preterm. Two thousand five
hundred twenty-nine (23.4%) were exposed to maternal smoking
during the first year, and 641 (6.0%) attended day care during the
first year. Two thousand eight hundred seventy-four (26.1%)
participants had wheezing reported at 6 months: the proportion of
participants with reported wheezing decreased to 1,756 (17.6%)
by 3½ years, 1,050 (12.9%) by 8½ years, and 592 (10.5%) by 16½
years. Of 6,691 participants with data available on skin prick tests
at 7½ years, 1,403 (21.0%) were atopic. Comparing the samples
of children with complete (n 5 3,170) and incomplete data
(>_2 observations of wheeze, n5 9,133) on wheezing in Table E1,
we observed that incomplete data are associated with markers of
social deprivation: increased exposure to tobacco smoke,
maternal anxiety, maternal lower education, parity, low
birthweight, and preterm delivery in those subsequently lost to
follow up. Also, the proportion of wheezing differs between 6
and 69 months but is similar thereafter, which is consistent with
less wheezing reported among children with complete data
compared with those subsequently lost to follow-up. Our analyses
included children with incomplete data on wheeze, avoiding bias
that could be introduced in complete case analyses.
Male sex (adjusted multinomial odds ratio [mOR] range, 1.32-
1.80) was associated with a similar higher risk of each phenotype
(heterogeneity P 5 .13, see Table E2). Maternal lower education
level was associated with a higher risk of midchildhood-onset
remitting wheeze (mOR, 1.22 [95% CI, 1.02-1.45] with little ev-
idence of heterogeneity; P 5 .11). Having at least 1 sibling was
associated with preschool- and midchildhood-onset remitting
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dence for association with the other phenotypes (heterogeneity
P5 .0012). Maternal history of asthma or allergy was associated
with a higher risk of each wheezing phenotype (mOR, 1.27-2.30,
heterogeneity P <.0001), and the strongest associations werewith
midchildhood-onset remitting (mOR, 1.65 [95% CI, 1.40-1.93])
and continuous (mOR, 2.30 [95% CI, 1.88-2.81]) wheezing.
Maternal smoking during pregnancy was associated with a higher
risk of preschool- and midchildhood-onset remitting and contin-
uous wheeze phenotypes (mOR, 1.33-1.46; heterogeneity
P 5 .71). Prenatal maternal anxiety was associated with a higher
risk of each wheezing phenotype (mOR, 1.12-1.29; heterogeneity
P 5 .08). Low birth weight was associated with continuous
wheeze (mOR, 1.63 [95% CI, 1.00-2.64]; heterogeneity
P5 .26). Preterm delivery was associated with higher risk of pre-
school- and midchildhood-onset remitting and continuous
wheezing (mOR, 1.35-1.63; heterogeneity P 5 .30). Day careattendance during the first year was associated with a higher
risk of preschool-onset remitting wheeze phenotype, although
we found little evidence of heterogeneity (P5 .16). We found lit-
tle evidence of an association between maternal smoking during
the first year and any of the wheezing phenotypes.REFERENCES
E1. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort
Profile: The ‘Children of the 90s’–the index offspring of the Avon Longitudinal
Study of Parents and Children. Int J Epidemiol 2013;42:111-27.
E2. Roberts G, Peckitt C, Northstone K, Strachan D, Lack G, Henderson J, et al. Rela-
tionship between aeroallergen and food allergen sensitization in childhood. Clin
Exp Allergy 2005;35:933-40.
E3. Henderson J, Granell R, Heron J, Sherriff A, Simpson A, Woodcock AA, et al. As-
sociations of wheezing phenotypes in the first six years of life with atopy, lung
function and airway responsiveness in mid childhood. Thorax 2008;63:974-80.
E4. Birtchnell J, Evans C, Kennard J. The total score of the Crown-Crisp Experiential
Index: a useful and valid measure of psychoneurotic pathology. Br J Med Psychol
1988;61:255-66.
FIG E1. Estimated prevalence of wheezing at each time point from birth to 16½ years for each of the 6
wheezing phenotypes identified by using latent class analysis in 12,303 children with at least 2 observations
of wheeze, including atopic status as a covariate in the model.
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FIG E2. Distribution of 12,303 children with 2 to 14 (complete data) observations of wheeze.
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TABLE E1. Characteristics of children with at least 2 observations of wheeze (study population, n 5 12,303) who did and did not
have complete data on wheezing
Children with complete data
on wheezing (n1 5 3,170)
Children with 2-13 observations
of wheezing (n2 5 9,133)
Two-sample test
of proportions
No./total Percent No./total Percent P value
Potential confounders
Male sex 1,560/3,170 49.2 4,770/9,133 52.2 .003
Lower maternal education* 1,547/3,151 49.1 5,614/8,184 68.6 <.0001
Having >_1 sibling (parity) 1,597/3,118 51.2 4,551/8,072 56.4 <.0001
Maternal history of asthma or allergy 1,510/3,107 48.6 3,629/8,025 45.2 .001
Maternal smoking during pregnancy 439/3,127 14.0 2,495/8,096 30.8 <.0001
Maternal anxiety during pregnancy 479/3,020 15.9 1,831/7,520 24.3 <.0001
Low birth weight (<2.5 kg) 134/3,134 4.3 441/8,397 5.3 .032
Preterm delivery (<37 wk) 153/3,170 4.8 529/8,504 6.2 .004
Maternal smoking during first year 411/3,122 13.2 2,118/7,690 27.5 <.0001
Day care attendance during first year 242/3,124 7.7 399/7,505 5.3 <.0001
Variables used in the latent class model
Reported wheezing at:
6 mo 709/3,170 22.4 2,165/7,834 27.6 <.0001
18 mo 780/3,170 24.6 2,205/7,691 28.7 <.0001
30 mo 612/3,170 19.3 1,632/6,775 24.1 <.0001
42 mo (3½ y) 487/3,170 15.4 1,269/6,803 18.7 <.0001
54 mo 505/3,170 15.9 1,269/6,221 20.4 <.0001
69 mo 435/3,170 13.7 893/5,426 16.5 .0007
81 mo 393/3,170 12.4 734/5,225 14.0 .70
91 mo 334/3,170 10.5 544/5,032 10.8 .14
103 mo (8½ y) 386/3,170 12.2 664/4,990 13.3 .41
128 mo 376/3,170 11.9 559/4,475 12.5 .37
140 mo 360/3,170 11.4 509/4,229 12.0 .83
157 mo 338/3,170 10.7 402/3,828 10.5 .44
166 mo 339/3,170 10.7 424/3,760 11.3 .86
198 mo (16½ y) 335/3,170 10.6 257/2,465 10.4 .39
Atopy at 7½ y (skin prick test) 524/2,433 21.5 879/4,258 20.6 .70
*Educated to General Certificate of Education level (school-leaving certificate) or lower.
Defined as being in the fourth quantile of the Crown-Crisp Experiential Index.
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TABLE E2. Associations of possible confounders with wheezing phenotypes at 0 to 16½ years and asthma at 14 years (based on
12,303 children with at least 2 observations of wheezing)
Adjusted multinomial OR (95% CI) Adjusted OR
(95% CI) for ever
doctor-diagnosed
asthma at 14 y
(n 5 5,838)
Preschool-onset
remitting
wheeze*
(n 5 1,605)
Midchildhood-
onset remitting
wheeze*
(n 5 620)
School-age–
onset persisting
wheeze*
(n 5 346)
Late childhood–
onset persisting
wheeze*
(n 5 324)
Continuous
wheeze*
(n 5 420)
Heterogeneity
P valuey
Demographic, maternal, pregnancy, and child characteristics (adjusted by each other)
Male sex 1.39 (1.25-1.55) 1.41 (1.21-1.66) 1.54 (1.26-1.89) 1.32 (1.09-1.60) 1.80 (1.48-2.19) .13 1.26 (1.11-1.42)
Maternal lower
education level
0.96 (0.86-1.08) 1.22 (1.02-1.45) 0.92 (0.74-1.13) 0.94 (0.77-1.14) 0.95 (0.77-1.16) .11 1.13 (1.00-1.28)
Parity 1.24 (1.11-1.38) 1.38 (1.17-1.62) 0.88 (0.72-1.07) 1.02 (0.85-1.24) 1.37 (1.12-1.67) 1.2E-03 0.95 (0.84-1.07)
Maternal history of
asthma or allergy
1.27 (1.14-1.42) 1.65 (1.40-1.93) 1.47 (1.20-1.80) 1.42 (1.17-1.72) 2.30 (1.88-2.81) 1.9E-06 1.53 (1.35-1.73)
Maternal smoking
during pregnancy
1.33 (1.17-1.51) 1.46 (1.22-1.75) 1.23 (0.97-1.56) 1.24 (0.99-1.56) 1.38 (1.10-1.72) .71 1.19 (1.01-1.39)
Maternal anxiety
during pregnancy
1.20 (1.14-1.26) 1.25 (1.16-1.35) 1.12 (1.02-1.23) 1.14 (1.04-1.24) 1.29 (1.18-1.41) .08 1.13 (1.07-1.20)
Perinatal characteristics adjusted by demographic, maternal, pregnancy, and child characteristics
Low birth weight
(<2.5 kg)§
1.00 (0.73-1.37) 1.14 (0.73-1.78) 1.47 (0.86-2.52) 1.56 (0.93-2.60) 1.63 (1.00-2.64) .26 1.11 (0.77-1.61)
Preterm delivery
(<37 wk)§
1.35 (1.07-1.70) 1.43 (1.03-2.00) 1.04 (0.65-1.67) 0.94 (0.59-1.50) 1.63 (1.11-2.39) .30 1.16 (0.87-1.56)
Postnatal characteristics adjusted by demographic, maternal, pregnancy, child, perinatal, and other postnatal characteristics
Maternal smoking
during first year
1.22 (0.98-1.51) 1.15 (0.84-1.58) 0.96 (0.64-1.44) 1.01 (0.69-1.49) 1.09 (0.74-1.61) .80 1.06 (0.82-1.37)
Day care attendance
during first year
1.28 (1.02-1.60) 0.97 (0.66-1.41) 0.72 (0.44-1.18) 0.92 (0.59-1.42) 1.07 (0.70-1.63) .16 0.90 (0.70-1.17)
*Compared with never/infrequent wheezing (n 5 6,305) and using each child’s phenotype probability as weights.
x2 Test across phenotypes.
Educated to school-leaving certificate at 16 years (General Certificate of Education level) or lower.
§Low birth weight was also adjusted by preterm delivery, but preterm delivery was not adjusted for low birth weight (because birth weight does not influence gestational age).
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TABLE E3. Crude associations of wheezing phenotypes at 0 to 16½ years with doctor-diagnosed asthma ever, FENO values of
35 ppb or greater, and BDR of greater than 12% at 14 to 15 years (based on 12,303 children with >_2 observations of wheeze)
Wheezing phenotype at 0-16½ y
Doctor-diagnosed asthma ever at 14 y FENO >_35 ppb at 14-15 y BDR >12% at 15 y
No. of asthmatic patients/total* OR (95% CI) n1/total* OR (95% CI) n2/total* OR (95% CI)
Never/infrequent wheeze 272/3,661 1 (reference) 290/1,157 1 (reference) 139/2,003 1 (reference)
Preschool-onset remitting wheeze 173/870 2.74 (2.23-3.36) 61/243 1.06 (0.79-1.44) 33/472 1.10 (0.76-1.59)
Midchildhood-onset remitting wheeze 231/337 25.0 (19.4-32.2) 42/102 1.93 (1.28-2.90) 21/204 1.66 (1.04-2.63)
School-age–onset persisting wheeze 187/223 49.9 (35.3-70.7) 57/82 6.39 (3.95-10.34) 27/127 3.28 (2.06-5.22)
Late childhood–onset persisting wheeze 161/250 19.8 (15.0-26.1) 38/66 3.67 (2.30-5.85) 19/131 2.10 (1.26-3.48)
Continuous wheeze 246/254 363 (179-735) 49/71 6.95 (4.13-11.72) 19/126 2.36 (1.40-3.98)
n1, Number of children with FENO values of 20 ppb or greater; n2, number of children with BDR of greater than 12%.
*Number of children with data available (approximated from modal assignment).
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TABLE E4. Crude association of wheezing phenotypes at 0 to 16½ years with lung function measures at 15 years (z scores) based
on 12,303 children with at least 2 observations of wheezing
Wheezing phenotype
at 0-16½ y
FEV1 (SDU) at 15 y FVC (SDU) at 15 y FEV1/FVC ratio (SDU) at 15 y FEF25-75 (SDU) at 15 y
No.*
Mean difference
(95% CI) No.*
Mean difference
(95% CI) No.*
Mean difference
(95% CI) No.*
Mean difference
(95% CI)
Never/infrequent wheeze 1,997 0 (reference) 2,094 0 (reference) 1,997 0 (reference) 2,094 0 (reference)
Preschool-onset remitting 463 20.02 (20.12 to 0.07) 477 0.05 (20.04 to 0.14) 463 20.15 (20.24 to 20.05) 477 20.13 (20.22 to 20.03)
Midchildhood-onset
remitting wheeze
203 0.09 (20.05 to 0.23) 209 0.21 (0.07 to 0.35) 203 20.23 (20.37 to 20.08) 209 20.14 (20.28 to 20.00)
School-age–onset
persisting wheeze
127 0.08 (20.10 to 0.26) 131 0.18 (0.00 to 0.35) 127 20.21 (20.39 to 20.04) 131 20.14 (20.32 to 0.03)
Late childhood–onset
persisting wheeze
130 20.02 (20.19 to 0.15) 135 0.02 (20.14 to 0.19) 130 20.08 (20.25 to 0.08) 135 20.21 (20.37 to 20.04)
Continuous wheeze 126 20.08 (20.26 to 0.10) 131 0.04 (20.14 to 0.22) 126 20.26 (20.44 to 20.08) 131 20.30 (20.48 to 20.12)
*Number of children with data available (approximated from modal assignment).
J ALLERGY CLIN IMMUNOL
OCTOBER 2016
1070.e8 GRANELL, HENDERSON, AND STERNE
TABLE E5. Adjusted associations of wheezing phenotypes at 0 to 16½ years with lung function measures at 8 years (z scores) in
participants with at least 2 observations of wheeze
Wheezing phenotype
at 0-16½ years
FEV1 (SDU) at 8 y FVC (SDU) at 8 y FEV1/FVC ratio (SDU) at 8 y FEF25-75 (SDU) at 8 y
No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y
Never/infrequent
wheeze
3,394 0 (reference) 3,452 0 (reference) 3,295 0 (reference) 3,452 0 (reference)
Preschool-onset
remitting wheeze
872 20.20 (20.28 to 20.13) 884 20.06 (20.13 to 0.02) 851 20.24 (20.31 to 20.17) 884 20.28 (20.35 to 20.21)
Midchildhood-onset
remitting wheeze
336 20.23 (20.34 to 20.12) 341 20.01 (20.11 to 0.10) 329 20.37 (20.48 to 20.26) 341 20.41 (20.51 to 20.30)
School-age–onset
persisting wheeze
219 20.30 (20.43 to 20.16) 222 20.01 (20.14 to 0.12) 215 20.44 (20.58 to 20.31) 222 20.48 (20.62 to 20.35)
Late childhood–onset
persisting wheeze
212 20.23 (20.36 to 20.11) 215 20.08 (20.21 to 0.05) 207 20.21 (20.34 to 20.08) 215 20.30 (20.43 to 20.18)
Continuous wheeze 245 20.40 (20.53 to 20.27) 249 0.10 (20.03 to 0.23) 236 20.78 (20.91 to 20.65) 249 20.75 (20.88 to 20.62)
*Number of participants with data available (approximated from modal assignment).
Adjusted for sex, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight, and day care attendance during
first year.
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TABLE E6. Adjusted associations of wheezing phenotypes at 0 to 16½ years with presalbutamol lung function measures at
15 years (z scores) in participants with at least 2 observations of wheeze
Wheezing phenotype
at 0-16½ y
FEV1 (SDU) at 15 y FVC (SDU) at 15 y FEV1/FVC ratio (SDU) at 15 y FEF25-75 (SDU) at 15 y
No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y
Never/infrequent
wheeze
2,064 0 (reference) 2,092 0 (reference) 2,064 0 (reference) 2,091 0 (reference)
Preschool-onset
remitting wheeze
473 20.06 (20.16 to 0.03) 477 0.05 (20.05 to 0.14) 473 20.21 (20.31 to 20.12) 476 20.16 (20.25 to 20.06)
Midchildhood-onset
remitting wheeze
207 20.03 (20.17 to 0.11) 209 0.16 (0.02 to 0.30) 207 20.35 (20.49 to 20.22) 209 20.25 (20.39 to 20.11)
School-age–onset
persisting wheeze
129 20.16 (20.33 to 0.02) 131 0.08 (20.10 to 0.25) 129 20.45 (20.62 to 20.28) 131 20.40 (20.57 to 20.22)
Late childhood–onset
persisting wheeze
135 20.20 (20.36 to 20.03) 135 20.04 (20.21 to 0.13) 135 20.29 (20.45 to 20.13) 135 20.33 (20.50 to 20.17)
Continuous wheeze 128 20.23 (20.41 to 20.04) 130 0.04 (20.14 to 0.22) 128 20.54 (20.72 to 20.37) 130 20.53 (20.71 to 20.35)
*Number of participants with data available (approximated from modal assignment).
Adjusted for sex, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight, and day care attendance during
first year.
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TABLE E7. Adjusted associations of wheezing phenotypes at 0 to 16½ years with lung function measures at 15 years
(presalbutamol z scores) further adjusted by lung function measures at 8 years (presalbutamol z scores) in participants with at
least 2 observations of wheeze
Wheezing phenotype
at 0-16½ y
FEV1 (SDU) at 15 y FVC (SDU) at 15 y FEV1/FVC ratio (SDU) at 15 y FEF25-75 (SDU) at 15 y
No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y No.*
Adjusted mean
difference (95% CI)y
Never/infrequent
wheeze
1,784 0 (reference) 1,826 0 (reference) 1,743 0 (reference) 1,825 0 (reference)
Preschool-onset
remitting wheeze
415 0.02 (20.08 to 0.11) 422 0.08 (20.01 to 0.17) 407 20.16 (20.25 to 20.07) 421 20.03 (20.12 to 0.06)
Midchildhood-onset
remitting wheeze
183 0.08 (20.05 to 0.22) 187 0.17 (0.04 to 0.31) 179 20.22 (20.36 to 20.09) 187 20.02 (20.15 to 0.11)
School-age–onset
persisting wheeze
110 20.05 (20.22 to 0.13) 113 0.11 (20.06 to 0.28) 110 20.33 (20.50 to 20.16) 113 20.19 (20.36 to 20.03)
Late childhood–onset
persisting wheeze
117 20.07 (20.24 to 0.09) 118 0.02 (20.14 to 0.18) 117 20.21 (20.37 to 20.05) 118 20.17 (20.32 to 20.01)
Continuous wheeze 106 20.04 (20.22 to 0.14) 110 0.06 (20.12 to 0.23) 103 20.25 (20.42 to 20.07) 110 20.14 (20.31 to 0.03)
*Number of participants with data available (approximated from modal assignment).
Adjusted for sex, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight, and day care attendance during
first year and additionally for lung function at 8 years.
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